Funder: National Institutes of Health
Due Dates: November 5, 2026 (Renewal/resubmission/revision) | February 5, 2027 (New) | March 5, 2027 (Renewal/resubmission/revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/resubmission/revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/resubmission/revision) | January 7, 2028 (Closing date)
Funding Amounts: Award ceiling: $499,000; application budgets limited to $499,000 in direct costs annually for up to 5 years
Summary: NCI supports academic-industrial partnerships translating technologies, methods, assays, devices, and systems into useful capabilities for research and cancer care.
Key Information: Each partnership must include at least one academic and one industrial organization.
Description
The National Cancer Institute (NCI) administers this NIH R01 program to translate scientific discoveries and engineering developments into tools for disease risk assessment, detection, prevention, diagnosis, treatment, and monitoring. Interdisciplinary, multi-institutional teams should enhance, adapt, optimize, or validate technologies beyond demonstration of possibility toward practical use in preclinical, clinical, or nonclinical settings.
The program seeks better cancer screening and early detection, accurate diagnosis and prognosis, and improved treatment and disease control. Supported work can include imaging, molecular diagnostics, informatics, artificial intelligence, quality assurance, and cross-platform validation. Innovation means the likelihood of delivering a new capability to end users, rather than technical novelty alone. Clinical trials are optional and may test functionality or validate performance when translation is their primary motivation.
